Visual Acuity in Aniridia and WAGR Syndrome
Our purpose was to evaluate visual acuity in aniridia subjects and the more severely affected phenotype in WAGR syndrome subjects, and to assess potential impact on visual function. This was a retrospective comparative study of 25 aniridia subjects with nonsense mutations of PAX6 (50 eyes) and 25 WA...
Saved in:
Published in | Clinical ophthalmology (Auckland, N.Z.) Vol. 17; pp. 1255 - 1261 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
New Zealand
Dove Medical Press Limited
01.01.2023
Dove Dove Medical Press |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Our purpose was to evaluate visual acuity in aniridia subjects and the more severely affected phenotype in WAGR syndrome subjects, and to assess potential impact on visual function.
This was a retrospective comparative study of 25 aniridia subjects with nonsense mutations of PAX6 (50 eyes) and 25 WAGR syndrome subjects with large deletion mutations involving PAX6 (50 eyes). Aniridia subjects were age- and gender-matched with WAGR syndrome subjects in the Coordination of Rare Diseases at Sanford (CoRDS) database. Best-corrected ETDRS visual acuity measurements were converted to LogMAR visual acuity values, which were used to perform statistical analyses.
The age and gender distribution of the subjects was not statistically significantly different. The mean LogMAR values in aniridia and WAGR syndrome subjects were 0.95±0.53 and 1.51±0.99, respectively (P<0.001). In the better-seeing eye, mean LogMAR values were 0.78±0.15 in aniridia subjects and 1.40±0.88 in WAGR syndrome subjects (P=0.001). The mean LogMAR values for the better-seeing eye corresponded to Snellen visual acuity of 20/125 in aniridia subjects and 20/500 in WAGR syndrome subjects. This average visual acuity was worse than the threshold for profound visual impairment (WHO criteria) and legal blindness (AAO criteria) in WAGR syndrome but not in aniridia subjects. In analysis of both eyes, the visual efficiency was 34% in aniridia subjects and 2% in WAGR syndrome subjects.
Visual acuity was significantly worse in WAGR subjects with multi-gene deletion mutations compared with aniridia subjects with nonsense mutations, which corresponded to differences in standard visual function thresholds. Our results suggest that visual acuity may indicate severity of ocular involvement and variability of phenotype in aniridia and WAGR syndrome. |
---|---|
AbstractList | Purpose: Our purpose was to evaluate visual acuity in aniridia subjects and the more severely affected phenotype in WAGR syndrome subjects, and to assess potential impact on visual function. Materials and Methods: This was a retrospective comparative study of 25 aniridia subjects with nonsense mutations of PAX6 (50 eyes) and 25 WAGR syndrome subjects with large deletion mutations involving PAX6 (50 eyes). Aniridia subjects were age- and gender-matched with WAGR syndrome subjects in the Coordination of Rare Diseases at Sanford (CoRDS) database. Best-corrected ETDRS visual acuity measurements were converted to LogMAR visual acuity values, which were used to perform statistical analyses. Results: The age and gender distribution of the subjects was not statistically significantly different. The mean LogMAR values in aniridia and WAGR syndrome subjects were 0.95 [+ or -] 0.53 and 1.51 [+ or -] 0.99, respectively (P<0.001). In the better-seeing eye, mean LogMAR values were 0.78 [+ or -] 0.15 in aniridia subjects and 1.40 [+ or -] 0.88 in WAGR syndrome subjects (P=0.001). The mean LogMAR values for the better-seeing eye corresponded to Snellen visual acuity of 20/125 in aniridia subjects and 20/500 in WAGR syndrome subjects. This average visual acuity was worse than the threshold for profound visual impairment (WHO criteria) and legal blindness (AAO criteria) in WAGR syndrome but not in aniridia subjects. In analysis of both eyes, the visual efficiency was 34% in aniridia subjects and 2% in WAGR syndrome subjects. Conclusion: Visual acuity was significantly worse in WAGR subjects with multi- gene deletion mutations compared with aniridia subjects with nonsense mutations, which corresponded to differences in standard visual function thresholds. Our results suggest that visual acuity may indicate severity of ocular involvement and variability of phenotype in aniridia and WAGR syndrome. Keywords: aniridia, WAGR syndrome, WAGR spectrum, PAX6, visual impairment, blindness Michael A Krause,1 Kelly L Trout,2 James D Lauderdale,3 Peter A Netland1 1Department of Ophthalmology, University of Virginia School of Medicine, Charlottesville, VA, USA; 2International WAGR Syndrome Association, Montgomery Village, MD, USA; 3Department of Cellular Biology, University of Georgia, Athens, GA, USACorrespondence: Peter A Netland, Department of Ophthalmology, University of Virginia School of Medicine, 1300 Jefferson Park Avenue, P.O. Box 800715, Charlottesville, VA, 22908-0715, USA, Tel +1 434-982-1086, Email pnetland@virginia.eduPurpose: Our purpose was to evaluate visual acuity in aniridia subjects and the more severely affected phenotype in WAGR syndrome subjects, and to assess potential impact on visual function.Materials and Methods: This was a retrospective comparative study of 25 aniridia subjects with nonsense mutations of PAX6 (50 eyes) and 25 WAGR syndrome subjects with large deletion mutations involving PAX6 (50 eyes). Aniridia subjects were age- and gender-matched with WAGR syndrome subjects in the Coordination of Rare Diseases at Sanford (CoRDS) database. Best-corrected ETDRS visual acuity measurements were converted to LogMAR visual acuity values, which were used to perform statistical analyses.Results: The age and gender distribution of the subjects was not statistically significantly different. The mean LogMAR values in aniridia and WAGR syndrome subjects were 0.95± 0.53 and 1.51± 0.99, respectively (P< 0.001). In the better-seeing eye, mean LogMAR values were 0.78± 0.15 in aniridia subjects and 1.40± 0.88 in WAGR syndrome subjects (P=0.001). The mean LogMAR values for the better-seeing eye corresponded to Snellen visual acuity of 20/125 in aniridia subjects and 20/500 in WAGR syndrome subjects. This average visual acuity was worse than the threshold for profound visual impairment (WHO criteria) and legal blindness (AAO criteria) in WAGR syndrome but not in aniridia subjects. In analysis of both eyes, the visual efficiency was 34% in aniridia subjects and 2% in WAGR syndrome subjects.Conclusion: Visual acuity was significantly worse in WAGR subjects with multi-gene deletion mutations compared with aniridia subjects with nonsense mutations, which corresponded to differences in standard visual function thresholds. Our results suggest that visual acuity may indicate severity of ocular involvement and variability of phenotype in aniridia and WAGR syndrome.Keywords: aniridia, WAGR syndrome, WAGR spectrum, PAX6, visual impairment, blindness Our purpose was to evaluate visual acuity in aniridia subjects and the more severely affected phenotype in WAGR syndrome subjects, and to assess potential impact on visual function.PurposeOur purpose was to evaluate visual acuity in aniridia subjects and the more severely affected phenotype in WAGR syndrome subjects, and to assess potential impact on visual function.This was a retrospective comparative study of 25 aniridia subjects with nonsense mutations of PAX6 (50 eyes) and 25 WAGR syndrome subjects with large deletion mutations involving PAX6 (50 eyes). Aniridia subjects were age- and gender-matched with WAGR syndrome subjects in the Coordination of Rare Diseases at Sanford (CoRDS) database. Best-corrected ETDRS visual acuity measurements were converted to LogMAR visual acuity values, which were used to perform statistical analyses.Materials and MethodsThis was a retrospective comparative study of 25 aniridia subjects with nonsense mutations of PAX6 (50 eyes) and 25 WAGR syndrome subjects with large deletion mutations involving PAX6 (50 eyes). Aniridia subjects were age- and gender-matched with WAGR syndrome subjects in the Coordination of Rare Diseases at Sanford (CoRDS) database. Best-corrected ETDRS visual acuity measurements were converted to LogMAR visual acuity values, which were used to perform statistical analyses.The age and gender distribution of the subjects was not statistically significantly different. The mean LogMAR values in aniridia and WAGR syndrome subjects were 0.95±0.53 and 1.51±0.99, respectively (P<0.001). In the better-seeing eye, mean LogMAR values were 0.78±0.15 in aniridia subjects and 1.40±0.88 in WAGR syndrome subjects (P=0.001). The mean LogMAR values for the better-seeing eye corresponded to Snellen visual acuity of 20/125 in aniridia subjects and 20/500 in WAGR syndrome subjects. This average visual acuity was worse than the threshold for profound visual impairment (WHO criteria) and legal blindness (AAO criteria) in WAGR syndrome but not in aniridia subjects. In analysis of both eyes, the visual efficiency was 34% in aniridia subjects and 2% in WAGR syndrome subjects.ResultsThe age and gender distribution of the subjects was not statistically significantly different. The mean LogMAR values in aniridia and WAGR syndrome subjects were 0.95±0.53 and 1.51±0.99, respectively (P<0.001). In the better-seeing eye, mean LogMAR values were 0.78±0.15 in aniridia subjects and 1.40±0.88 in WAGR syndrome subjects (P=0.001). The mean LogMAR values for the better-seeing eye corresponded to Snellen visual acuity of 20/125 in aniridia subjects and 20/500 in WAGR syndrome subjects. This average visual acuity was worse than the threshold for profound visual impairment (WHO criteria) and legal blindness (AAO criteria) in WAGR syndrome but not in aniridia subjects. In analysis of both eyes, the visual efficiency was 34% in aniridia subjects and 2% in WAGR syndrome subjects.Visual acuity was significantly worse in WAGR subjects with multi-gene deletion mutations compared with aniridia subjects with nonsense mutations, which corresponded to differences in standard visual function thresholds. Our results suggest that visual acuity may indicate severity of ocular involvement and variability of phenotype in aniridia and WAGR syndrome.ConclusionVisual acuity was significantly worse in WAGR subjects with multi-gene deletion mutations compared with aniridia subjects with nonsense mutations, which corresponded to differences in standard visual function thresholds. Our results suggest that visual acuity may indicate severity of ocular involvement and variability of phenotype in aniridia and WAGR syndrome. Our purpose was to evaluate visual acuity in aniridia subjects and the more severely affected phenotype in WAGR syndrome subjects, and to assess potential impact on visual function. This was a retrospective comparative study of 25 aniridia subjects with nonsense mutations of PAX6 (50 eyes) and 25 WAGR syndrome subjects with large deletion mutations involving PAX6 (50 eyes). Aniridia subjects were age- and gender-matched with WAGR syndrome subjects in the Coordination of Rare Diseases at Sanford (CoRDS) database. Best-corrected ETDRS visual acuity measurements were converted to LogMAR visual acuity values, which were used to perform statistical analyses. The age and gender distribution of the subjects was not statistically significantly different. The mean LogMAR values in aniridia and WAGR syndrome subjects were 0.95±0.53 and 1.51±0.99, respectively (P<0.001). In the better-seeing eye, mean LogMAR values were 0.78±0.15 in aniridia subjects and 1.40±0.88 in WAGR syndrome subjects (P=0.001). The mean LogMAR values for the better-seeing eye corresponded to Snellen visual acuity of 20/125 in aniridia subjects and 20/500 in WAGR syndrome subjects. This average visual acuity was worse than the threshold for profound visual impairment (WHO criteria) and legal blindness (AAO criteria) in WAGR syndrome but not in aniridia subjects. In analysis of both eyes, the visual efficiency was 34% in aniridia subjects and 2% in WAGR syndrome subjects. Visual acuity was significantly worse in WAGR subjects with multi-gene deletion mutations compared with aniridia subjects with nonsense mutations, which corresponded to differences in standard visual function thresholds. Our results suggest that visual acuity may indicate severity of ocular involvement and variability of phenotype in aniridia and WAGR syndrome. |
Audience | Academic |
Author | Lauderdale, James D Trout, Kelly L Netland, Peter A Krause, Michael A |
Author_xml | – sequence: 1 givenname: Michael A surname: Krause fullname: Krause, Michael A – sequence: 2 givenname: Kelly L surname: Trout fullname: Trout, Kelly L – sequence: 3 givenname: James D surname: Lauderdale fullname: Lauderdale, James D – sequence: 4 givenname: Peter A orcidid: 0000-0002-9523-2650 surname: Netland fullname: Netland, Peter A |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37152637$$D View this record in MEDLINE/PubMed |
BookMark | eNptkstr3DAQxkVJaB7trediKJRAuls9LEs-FROaBwRSmqU9ClmPXQVbSiW7sP995O6m7Iagg8Tom5_m08wJOPDBGwA-IDjHqGRf734sruf3JaQQkjfgGCHGZrTk5GDnfAROUnqAsMKQs7fgiDBEcUXYMTj_5dIou6JRoxvWhfNF41102slCel38bq5-Fvdrr2PozTtwaGWXzPvtfgoWl98XF9ez27urm4vmdqZoWQ8zUnEuNSElpcjmpesa8hoayyFvJSTWcqoxqiAxLcTISs2trTllkKhSUXIKbjZYHeSDeIyul3EtgnTiXyDEpZBxcKozAhPNNTUKY8XK7LaFFmvacmVqVLWGZNa3DetxbHujlfFDlN0edP_Gu5VYhr8CQZQ_q56qOdsSYvgzmjSI3iVluk56E8YkMEcom6n49NinjXQpc23O25CRapKLhlFWVlXJeFbNX1HlpU3vVO6tdTm-l_B5J2FlZDesUujGwQWf9oUfd83-d_nc7SzAG4GKIaVorFBukBMnl-C6bFpMIyWmkRLbkcpJX14kPXNflT8BrfTH-A |
CitedBy_id | crossref_primary_10_1007_s11596_024_2903_1 crossref_primary_10_1016_j_jtos_2023_05_010 |
Cites_doi | 10.1016/j.preteyeres.2022.101133 10.1111/j.1755-3768.1980.tb08291.x 10.1136/jmedgenet-2019-106172 10.1016/S0161-6420(02)01839-0 10.3390/genes10121050 10.1038/ejhg.2012.100 10.2147/OPTH.S217930 10.1167/iovs.08-2827 10.1172/jci.insight.148406 10.1016/S0161-6420(13)38011-7 10.1016/j.ajo.2021.12.007 10.3928/1081-597X-19970701-16 10.3389/fped.2021.733018 10.1016/j.ophtha.2008.10.018 10.1186/s12886-022-02460-5 10.1016/j.survophthal.2021.02.011 10.3109/09286586.2015.1066394 10.1111/cge.12708 10.1056/NEJMoa054481 10.1016/j.ajo.2022.11.003 10.1542/peds.61.4.604 10.1542/peds.2004-0467 |
ContentType | Journal Article |
Copyright | 2023 Krause et al. COPYRIGHT 2023 Dove Medical Press Limited 2023 Krause et al. 2023 Krause et al. |
Copyright_xml | – notice: 2023 Krause et al. – notice: COPYRIGHT 2023 Dove Medical Press Limited – notice: 2023 Krause et al. 2023 Krause et al. |
DBID | AAYXX CITATION NPM 7X8 5PM DOA |
DOI | 10.2147/OPTH.S405003 |
DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Open Access Full Text |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | Krause et al |
EISSN | 1177-5483 |
EndPage | 1261 |
ExternalDocumentID | oai_doaj_org_article_23d8d5ec22c74117b0f2d5b8ce916be3 PMC10162095 A757466478 37152637 10_2147_OPTH_S405003 |
Genre | Journal Article |
GroupedDBID | --- 0YH 29B 2WC 53G 5VS 6J9 7X7 8AO 8FI 8FJ 8G5 AAYXX ABDBF ABUWG ACGFO ACUHS ADBBV ADRAZ AFKRA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BCNDV BENPR BPHCQ BVXVI C1A CCPQU CITATION DIK DWQXO E3Z EBD EBS EJD F5P FRP FYUFA GNUQQ GROUPED_DOAJ GUQSH GX1 HMCUK HYE IAO IHR IHW ITC KQ8 M2O M48 O5R O5S OK1 P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC RNS RPM TDBHL TR2 UKHRP VDV W2D M~E NPM PMFND 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c549t-3688ad334551f1f1d990890ef808ba03ff85d21603eb021fad8ff985703c4c53 |
IEDL.DBID | M48 |
ISSN | 1177-5483 1177-5467 |
IngestDate | Wed Aug 27 00:33:38 EDT 2025 Thu Aug 21 18:37:20 EDT 2025 Fri Jul 11 08:23:18 EDT 2025 Tue Jun 17 21:29:22 EDT 2025 Tue Jun 10 20:30:57 EDT 2025 Thu May 22 21:15:16 EDT 2025 Thu Jan 02 22:53:00 EST 2025 Thu Apr 24 22:58:54 EDT 2025 Tue Jul 01 02:21:51 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | visual impairment PAX6 WAGR spectrum WAGR syndrome blindness aniridia |
Language | English |
License | https://creativecommons.org/licenses/by-nc/3.0 2023 Krause et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c549t-3688ad334551f1f1d990890ef808ba03ff85d21603eb021fad8ff985703c4c53 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-9523-2650 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.2147/OPTH.S405003 |
PMID | 37152637 |
PQID | 2811216683 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_23d8d5ec22c74117b0f2d5b8ce916be3 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10162095 proquest_miscellaneous_2811216683 gale_infotracmisc_A757466478 gale_infotracacademiconefile_A757466478 gale_healthsolutions_A757466478 pubmed_primary_37152637 crossref_citationtrail_10_2147_OPTH_S405003 crossref_primary_10_2147_OPTH_S405003 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2023-01-01 |
PublicationDateYYYYMMDD | 2023-01-01 |
PublicationDate_xml | – month: 01 year: 2023 text: 2023-01-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | New Zealand |
PublicationPlace_xml | – name: New Zealand |
PublicationTitle | Clinical ophthalmology (Auckland, N.Z.) |
PublicationTitleAlternate | Clin Ophthalmol |
PublicationYear | 2023 |
Publisher | Dove Medical Press Limited Dove Dove Medical Press |
Publisher_xml | – name: Dove Medical Press Limited – name: Dove – name: Dove Medical Press |
References | ref12 ref14 Bobilev (ref7) 2016 Riccardi (ref8) 1978; 61 ref16 Cunha (ref23) 2019; 10 Netland (ref2) 2011; 15 Rosenfeld (ref13) 2006; 355 Hingorani (ref19) 2009; 50 Alafaleq (ref25) 2023; 247 Hingorani (ref6) 2012; 20 Daruich (ref22) 2022 Shiple (ref5) 2015; 9 Vasilyeva (ref21) 2021; 58 Eckert (ref26) 2015; 22 Bajwa (ref4) 2019; 13 Holladay (ref18) 1997; 13 Jacobson (ref27) 2022; 22 Brown (ref24) 2006; 116 Hyvarinen (ref17) 1980; 58 Saaddine (ref15) 2003; 110 Kit (ref20) 2021; 6 (ref3) 2015 Fischbach (ref9) 2005; 116 Daruich (ref11) 2022; 237 Duffy (ref10) 2021; 9 Landsend (ref1) 2021; 66 |
References_xml | – volume-title: Aniridia: Recent Developments in Scientific and Clinical Research year: 2015 ident: ref3 – start-page: 101133 year: 2022 ident: ref22 publication-title: Prog Retin Eye Res doi: 10.1016/j.preteyeres.2022.101133 – volume: 58 start-page: 507 year: 1980 ident: ref17 publication-title: Acta Ophthalmol doi: 10.1111/j.1755-3768.1980.tb08291.x – volume: 58 start-page: 270 year: 2021 ident: ref21 publication-title: J Med Genet doi: 10.1136/jmedgenet-2019-106172 – volume: 110 start-page: 253 year: 2003 ident: ref15 publication-title: Ophthalmology doi: 10.1016/S0161-6420(02)01839-0 – volume: 10 start-page: 1050 year: 2019 ident: ref23 publication-title: Genes doi: 10.3390/genes10121050 – volume: 9 start-page: 291 year: 2015 ident: ref5 publication-title: Clin Ophthalmol – volume: 20 start-page: 1011 year: 2012 ident: ref6 publication-title: Eur J Hum Genet doi: 10.1038/ejhg.2012.100 – volume: 13 start-page: 1469 year: 2019 ident: ref4 publication-title: Clin Ophthalmol doi: 10.2147/OPTH.S217930 – volume: 50 start-page: 2581 year: 2009 ident: ref19 publication-title: Investig Ophthalmol Vis Sci doi: 10.1167/iovs.08-2827 – volume: 6 start-page: 1 year: 2021 ident: ref20 publication-title: JCI Insight doi: 10.1172/jci.insight.148406 – ident: ref12 doi: 10.1016/S0161-6420(13)38011-7 – volume: 237 start-page: 122 year: 2022 ident: ref11 publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2021.12.007 – volume: 13 start-page: 388 year: 1997 ident: ref18 publication-title: J Refractive Surg doi: 10.3928/1081-597X-19970701-16 – volume: 9 start-page: 733018 year: 2021 ident: ref10 publication-title: Front Pediatr doi: 10.3389/fped.2021.733018 – volume: 15 start-page: 562 year: 2011 ident: ref2 publication-title: JAAPOS – volume: 116 start-page: 57 year: 2006 ident: ref24 publication-title: Ophthalmology doi: 10.1016/j.ophtha.2008.10.018 – volume: 22 start-page: 235 year: 2022 ident: ref27 publication-title: BMC Ophthalmol doi: 10.1186/s12886-022-02460-5 – volume: 66 start-page: 1031 year: 2021 ident: ref1 publication-title: Surv Ophthalmol doi: 10.1016/j.survophthal.2021.02.011 – volume: 22 start-page: 349 year: 2015 ident: ref26 publication-title: Ophthalmic Epidemiol doi: 10.3109/09286586.2015.1066394 – start-page: 1 year: 2016 ident: ref7 publication-title: Clin Genet doi: 10.1111/cge.12708 – volume: 355 start-page: 1419 year: 2006 ident: ref13 publication-title: N Engl J Med doi: 10.1056/NEJMoa054481 – volume: 247 start-page: 145 year: 2023 ident: ref25 publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2022.11.003 – volume: 61 start-page: 604 year: 1978 ident: ref8 publication-title: Pediatrics doi: 10.1542/peds.61.4.604 – volume: 116 start-page: 984 year: 2005 ident: ref9 publication-title: Pediatrics doi: 10.1542/peds.2004-0467 – ident: ref16 – ident: ref14 |
SSID | ssj0062087 |
Score | 2.3039618 |
Snippet | Our purpose was to evaluate visual acuity in aniridia subjects and the more severely affected phenotype in WAGR syndrome subjects, and to assess potential... Purpose: Our purpose was to evaluate visual acuity in aniridia subjects and the more severely affected phenotype in WAGR syndrome subjects, and to assess... Michael A Krause,1 Kelly L Trout,2 James D Lauderdale,3 Peter A Netland1 1Department of Ophthalmology, University of Virginia School of Medicine,... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 1255 |
SubjectTerms | aniridia Blindness Comparative analysis Diabetic retinopathy Genetic aspects Medical research Medicine, Experimental Original Research pax6 visual impairment wagr spectrum wagr syndrome |
SummonAdditionalLinks | – databaseName: DOAJ Open Access Full Text dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlh9JL6TN1m7YOpOQQnNiSLc8eN6HJUsiDZJvkJmQ9iKF4S7L7_ztjaZc1IeRSfLPGIM3D80kef8PYji29H1lwma-MycoRiAyERiDHJdiy8Ca3fYHsmZz8Ln_dVrdrrb6oJizQAwfFHXBhwVbOcG4w-RV1k3tuqwaMQ2DTuJ7nE3PecjMV3sGS5xDbqtQZYnIRSt6pJ8_B-cV0sn-FOCVfNsqKyajn7H_8Zl5LTcOyybU8dPyGvY4AMh2Hib9lL1z3jr08jZ_I37O96_ZhQQJmgQA7bbt03LX3LbpBqjub3oxPLtOrSFPwgU2Pf06PJlnsiJAZ3MfNMyEBtBWiRJzj8bIj-myXOw85NDoX3kNlOXWOdg0mb68toCmIw16Y0lTiI9voZp37xFLptcHo04WzHjc9XFs5ghyxBT7BeSEStrfUjDKRLZyaVvxRuGsgPSrSo4p6TNiPlfTfwJLxhNwhKXklQ9zW_Q20uIoWV89ZPGHfyUQq_Ci6ilA1rquayPJrSNhuL0ExipM2Ov5qgEsntquB5NZAEmPLDIa3l26gaIgK0jo3WzwoDghUCykBp7MZ3GK1KlEjKJKiThgMHGaw7OFI19711N50loLuXH3-H4r6wl5xhGThwGiLbczvF-4rQqh5862Pln95vRTH priority: 102 providerName: Directory of Open Access Journals |
Title | Visual Acuity in Aniridia and WAGR Syndrome |
URI | https://www.ncbi.nlm.nih.gov/pubmed/37152637 https://www.proquest.com/docview/2811216683 https://pubmed.ncbi.nlm.nih.gov/PMC10162095 https://doaj.org/article/23d8d5ec22c74117b0f2d5b8ce916be3 |
Volume | 17 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3da9RAEF9qC-KL-O1pPSMoPpTUZDfZnXsQuUrrIbSW9qrn05LshwZKTu8D9L93JtkLDVUkkIfsJOxOZjK_3Z38hrGXNvN-ZMHFPjcmzkYgYhAFAjkuwWapN4ltEmRP5OQi-zjLZ1tsU200KHD516kd1ZO6WFzu__r5-x06_FtKY04z9ebT6XSyf47Io6H93MGYpKiWwXHW7SdInkAos6JixOiiTYG_dncvODUc_te_1FdCVT-N8kpcOrrDbgdAGY1bC7jLtlx9j908Dlvm99ne52q5JgGzRsAdVXU0rqtFhWYRFbWNvow_nEXngbbgAZseHU7fT-JQISE2OK9bxUICFFaIDHGPx8OOaBsvcR4SKItEeA-55VRJ2pUYzH1hAV8NcdoLk5lcPGTb9bx2j1kkfWHQG4vUWY-TIF5YOYIEsQbewXkqBmxvoxltAns4FbG41DiLID1q0qMOehywV530j5Y14x9yB6TkToa4rpsL88U3HVxHc2HB5s5wbhD-pKpMPLd5CcYhtC0dPuQ5vSLd_jjaeaweq1wReb6CAXvdSJAVYadNEX49wKET-1VPcrcnib5mes0vNmagqYkS1Go3Xy81BwSuqZSA3XnUmkU3KqEQJEmhBgx6BtMbdr-lrr43VN-0tsIRBT_57xifslsc8Ve7OrTLtleLtXuGeGlVDtmN5OsEz2qmhmzn4PDk9GzYrD0MGyf5A5koE7U |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Visual+Acuity+in+Aniridia+and+WAGR+Syndrome&rft.jtitle=Clinical+ophthalmology+%28Auckland%2C+N.Z.%29&rft.au=Lauderdale%2C+James+D&rft.au=Krause%2C+Michael+A&rft.au=Netland%2C+Peter+A&rft.au=Trout%2C+Kelly+L&rft.date=2023-01-01&rft.pub=Dove+Medical+Press+Limited&rft.issn=1177-5483&rft.volume=17&rft.spage=1255&rft_id=info:doi/10.2147%2FOPTH.S405003&rft.externalDBID=n%2Fa&rft.externalDocID=A757466478 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1177-5483&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1177-5483&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1177-5483&client=summon |